Eylea

Roche eyes an uncertain market for faricimab
Roche eyes an uncertain market for faricimab
EP Vantage
Roche
faricimab
diabetic macular edema
Regeneron
Eylea
Flag link:
Roche's bispecific matches Regeneron's Eylea in phase 3 trials
Roche's bispecific matches Regeneron's Eylea in phase 3 trials
Fierce Biotech
Roche
faricimab
diabetic macular edema
clinical trials
Regeneron
Eylea
bispecific antibodies
Flag link:
Novartis raises the temp on Eylea rivalry with head-to-head trial win for Beovu in diabetic macular edema
Novartis raises the temp on Eylea rivalry with head-to-head trial win for Beovu in diabetic macular edema
Endpoints
Regeneron
Eylea
Novartis
Beovu
diabetic macular edema
Flag link:
Novartis says Beovu matched rival Eylea in visual acuity in eye disease
Novartis says Beovu matched rival Eylea in visual acuity in eye disease
Pharma Live
Novartis
Beovu
Eylea
Regeneron
diabetic macular edema
clinical trials
Flag link:
Bayer's Eylea shows pandemic resilience, but major China price cut drags on business
Bayer's Eylea shows pandemic resilience, but major China price cut drags on business
Fierce Pharma
Bayer
earnings
China
pandemic
COVID-19
Eylea
Flag link:
Regeneron vows ‘vigorous’ defense against allegations it paid kickbacks for eye drug
Regeneron vows ‘vigorous’ defense against allegations it paid kickbacks for eye drug
MedCity News
Regeneron
Eylea
Massachusetts
kickbacks
macular degeneration
Flag link:
Regeneron vows to fight DOJ lawsuit alleging charity donations were Eylea kickbacks
Regeneron vows to fight DOJ lawsuit alleging charity donations were Eylea kickbacks
Fierce Pharma
Regeneron
DOJ
Eylea
kickbacks
charity
Flag link:
AsclepiX Emerges With $35M and an Eye Drug Challenger to Eylea, Lucentis
AsclepiX Emerges With $35M and an Eye Drug Challenger to Eylea, Lucentis
Xconomy
AsclepiX Therapeutics
eye disease
Eylea
Lucentis
macular edema
wet age-related macular degeneration
retinal occulsion
AXT107
Flag link:
Regeneron touts Eylea strength as Novartis rival falters, COVID-19 cuts demand
Regeneron touts Eylea strength as Novartis rival falters, COVID-19 cuts demand
Fierce Pharma
Regeneron
Eylea
Novartis
Beovu
COVID-19
Flag link:
Does Regeneron Pharmaceuticals’ Winning Streak Signal Irrational Exuberance?
Does Regeneron Pharmaceuticals’ Winning Streak Signal Irrational Exuberance?
Motley Fool
Regeneron
Eylea
Dupixent
Flag link:
Novartis knocked by safety scare
Novartis knocked by safety scare
EP Vantage
Novartis
Regeneron
Beovu
Eylea
wet age-related macular degeneration
Flag link:
Regeneron’s Eylea delivers positive two-year results in PANORAMA trial
Regeneron’s Eylea delivers positive two-year results in PANORAMA trial
Pharmaceutical Business Review
Regeneron
Eylea
diabetic neuropathy
NPDR
clinical trials
Flag link:
Are Novartis and Regeneron seeing the same thing?
Are Novartis and Regeneron seeing the same thing?
BioPharma Dive
Novartis
Regeneron
physicians
Eylea
Beovu
Flag link:
Biogen signs marketing deal for two ophthalmology biosimilars
Biogen signs marketing deal for two ophthalmology biosimilars
Pharmaforum
Biogen
ophthalmology
biosimilars
Europe
Japan
Samsung Bioepis
SB11
SB15
Lucentis
Eylea
Flag link:
Regeneron profit beats expectations on Eylea, Dupixent strength
Regeneron profit beats expectations on Eylea, Dupixent strength
Yahoo/Reuters
Regeneron
earnings
Eylea
Dupixent
Flag link:
Eylea could be in trouble, but that doesn't make Regeneron a buyer
Eylea could be in trouble, but that doesn't make Regeneron a buyer
Biopharma Dive
Regeneron
M&A
Eylea
Flag link:
Eylea casts a shadow over Novartis' latest approval
Eylea casts a shadow over Novartis' latest approval
Biopharma Dive
Novartis
Beovu
wet age-related macular degeneration
Regeneron
Eylea
Flag link:
Novartis’ new eye drug undercuts Bayer’s rival with fewer injections
Novartis’ new eye drug undercuts Bayer’s rival with fewer injections
Pharmaforum
Novartis
brolucizumab
Bayer
Eylea
wet age-related macular degeneration
FDA
Flag link:
Novartis backs brolucizumab with new head-to-head Eylea trial
Novartis backs brolucizumab with new head-to-head Eylea trial
Pharmaforum
Novartis
clinical trials
brolucizumab
Eylea
Bayer
Regeneron
age-related macular degeneration
Flag link:
What could help biotech close out 2019 stronger? Analysts pick 3 events to watch
What could help biotech close out 2019 stronger? Analysts pick 3 events to watch
Biopharma Dive
Amgen
AMG 510
KRAS inhibitors
Roche
PTC Therapeutics
risdiplam
Eylea
Novartis
Flag link:

Pages